Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 12/07
3889JPY
-5.24%
Prev.4104.0000
Open4000.0000
High4032.0000
Low3859.0000
Volume17 163 200
Financials
Sales 2019 1 764 B
EBIT 2019 -
R. net 2019 142 B
Debt 2019 584 B
Rend. 2019 4,63%
P/E ratio 2019 21,44
P/E ratio 2020 17,88
EV / Sales 2019 2,08x
EV / Sales 2020 1,97x
Capitalization 3 091 B
Company
Takeda Pharmaceutical Company specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. Net sales break down by activity as follows:
- sale of drugs (95.5%);
- sale...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-03-27 TAKEDA PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
Trading Rating :
Investor Rating :
Latest news
04:40pSHIRE : Elliott Capital Advisors, L.P Elliott Capital -2-
DJ
04:40pELLIOTT CAPITAL ADVISORS, L.P ELLIOTT CAPITAL ADVISORS, L.P : Form 8.3 - Takeda Pharmaceutical Company Limited
DJ
12/07LONDON STOCK EXCHANGE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs
RE
12/07SHIRE : Elliott Capital Advisors, L.P Elliott Capital -2-
DJ
12/07ELLIOTT CAPITAL ADVISORS, L.P ELLIOTT CAPITAL ADVISORS, L.P : Form 8.3 - Shire Plc
DJ
12/07SHIRE : Elliott Capital Advisors, L.P Elliott Capital -2-
DJ
12/07ELLIOTT CAPITAL ADVISORS, L.P ELLIOTT CAPITAL ADVISORS, L.P : Form 8.3 - Takeda Pharmaceutical Co.Ltd
DJ
12/06TAKEDA PHARMACEUTICAL : to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBearish
Resistance4 3034 3034 861
Spread/Res.-9,6%-9,6%-20%
Spread/Supp.0,88%4,4%8,6%
Support3 8553 7253 580